13th January 2021

Rathbones: Investment Insights Q1 2021

Financial markets have been on a rollercoaster over the past year. There was a sharp drop in March as countries locked down and then a swift upswing followed, led by technology shares. Even unloved companies, particularly banks and energy firms, have rebounded lately, thanks to good news about vaccines.

We explore what’s likely to happen as vaccines are gradually rolled out and the global economy recovers in 2021. Many investors had shifted their portfolios away from stocks that were seen as winners of the pandemic into cheaper ‘value’ stocks that have been hard hit by lockdowns. Although we see limits to how much further this rotation can continue, we do believe a less cautious stance is now justified.

Investments, Investment Commentary, Partner Lead Story, Market Outlook

Registration

Free Registration and CPD

Rathbones Asset Management - The Sharpe End podcast: Fresh Intel

A month into Andy Burnham’s tenure as Prime Minister, the team are asking what he could possibly do to turn the UK economy and stock market around. Next, we explore the rally in software stocks, as improving growth expectations reignite enthusiasm for some names in the sector that many had written off just a year ago. Finally, this month’s stock spotlight is Intel – a company that helped build the modern technology industry and is now attempting an ambitious turnaround as a crucial beneficiary of the broad AI infrastructure build-out.

There's more to 'value' investing than valuations

Semantics matter. Words carry associations that can't always be neatly translated into a different cultural context. First impressions often determine whether investors are prepared to allocate money to an investment strategy.

Business Sentiment Tracker: Business confidence falls in Q2 2026

Business confidence has weakened in the second wave of YouGov's quarterly Business Sentiment Tracker, with businesses becoming less optimistic about the economy, their industries, and their own prospects.

You need to be logged in to comment on this article

About Us

Read

Learn

Attend

Connect

My Panacea

Press Centre